Pure Global
NCT06224764

Assessment of the Impact of the Return Home of Premature Newborns Less Than 2 Kilos Morbidity/Mortality

Assessment of the Impact of the Return Home of Premature Newborns With Intrauterine Growth Retardation Weighing Less Than 2 Kilos (Low Birth Weight) on Short- and Long-term Morbidity/Mortality
Hôpital NOVO·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Premature Birth
Drug/Device/Intervention
Mother and Father questionnaires
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Hôpital NOVO
Location
Pontoise, France
Timeline & enrollment
Phase
N/A
Start date
Feb 21, 2024
End date
Dec 01, 2024
Enrollment
40 participants
Primary outcome

Observation of the short-term outcome of neonates discharged from the neonatology department hospital (Pontoise site) between 2012 and 2023 with a weight of less than 2 kilos.

Summary

The aim of this study is to evaluate the impact of discharge from hospital with a weight of
 less than 2 kilos.
 
 To do this, the investigator will look at the short-term and long-term outcome of newborns
 weighing less than 2 kilos who were discharged from the neonatology department at the NOVO
 hospital between 2012 and 2023.

ICD-10 classifications
Fetus and newborn affected by precipitate deliveryPreterm delivery without spontaneous labourDisorders related to short gestation and low birth weight, not elsewhere classifiedOther preterm infantsPreterm spontaneous labour with preterm delivery
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06224764
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06224764 through Pure Global AI's free database. This phase not specified trial is sponsored by Hôpital NOVO and is currently Recruiting. The study focuses on Premature Birth. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.